A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Public ClinicalTrials.gov record NCT00615056. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase 2 Study Of FOLFOX Or FOLFIRI With AG-013736 Or Bevacizumab (Avastin) In Patients With Metastatic Colorectal Cancer After Failure Of An Irinotecan Or Oxaliplatin-Containing First-Line Regimen
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is designed to demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab (Avastin) in delaying tumor progression in the second-line treatment of patients with metastatic colorectal cancer after failure of an irinotecan or oxaliplatin-containing first-line regimen.
Study identification
- NCT ID
- NCT00615056
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 171 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab (avastin) Drug
- FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]) Drug
- AG-013736 (axitinib) Drug
- FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2008 (Type not available)
- Primary completion
- Mar 2011 (Actual)
- Completion
- Apr 2012 (Actual)
- Last update posted
- Apr 19, 2013
2008 – 2012
United States locations
- U.S. sites
- 61
- U.S. states
- 13
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Mobile | Alabama | 36608 | — |
| Pfizer Investigational Site | Antioch | California | 94531 | — |
| Pfizer Investigational Site | Los Angeles | California | 90095-6984 | — |
| Pfizer Investigational Site | Los Angeles | California | 90095 | — |
| Pfizer Investigational Site | Pleasant Hill | California | 94523 | — |
| Pfizer Investigational Site | San Leandro | California | 94578 | — |
| Pfizer Investigational Site | Santa Monica | California | 90404 | — |
| Pfizer Investigational Site | Aurora | Colorado | 80045 | — |
| Pfizer Investigational Site | Bonita Springs | Florida | 34135 | — |
| Pfizer Investigational Site | Bradenton | Florida | 34209 | — |
| Pfizer Investigational Site | Cape Coral | Florida | 33914 | — |
| Pfizer Investigational Site | Cape Coral | Florida | 33990 | — |
| Pfizer Investigational Site | Englewood | Florida | 34223 | — |
| Pfizer Investigational Site | Fort Myers | Florida | 33901-8108 | — |
| Pfizer Investigational Site | Fort Myers | Florida | 33905 | — |
| Pfizer Investigational Site | Fort Myers | Florida | 33908 | — |
| Pfizer Investigational Site | Fort Myers | Florida | 33916 | — |
| Pfizer Investigational Site | Naples | Florida | 34102 | — |
| Pfizer Investigational Site | Naples | Florida | 34119 | — |
| Pfizer Investigational Site | Port Charlotte | Florida | 33980 | — |
| Pfizer Investigational Site | Sarasota | Florida | 34232 | — |
| Pfizer Investigational Site | Sarasota | Florida | 34236 | — |
| Pfizer Investigational Site | Venice | Florida | 34285 | — |
| Pfizer Investigational Site | Venice | Florida | 34292 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30318 | — |
| Pfizer Investigational Site | Ringgold | Georgia | 30736 | — |
| Pfizer Investigational Site | Dubuque | Iowa | 52001 | — |
| Pfizer Investigational Site | Crestview Hills | Kentucky | 41017 | — |
| Pfizer Investigational Site | Paducah | Kentucky | 42002 | — |
| Pfizer Investigational Site | Paducah | Kentucky | 42003 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21237 | — |
| Pfizer Investigational Site | New Albany | Mississippi | 38652 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45219 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45230 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45236 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45238 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45242 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45248 | — |
| Pfizer Investigational Site | Fairfield | Ohio | 45014 | — |
| Pfizer Investigational Site | Hamilton | Ohio | 45013 | — |
| Pfizer Investigational Site | Chattanooga | Tennessee | 37404 | — |
| Pfizer Investigational Site | Franklin | Tennessee | 37067 | — |
| Pfizer Investigational Site | Gallatin | Tennessee | 37066 | — |
| Pfizer Investigational Site | Germantown | Tennessee | 38138 | — |
| Pfizer Investigational Site | Hermitage | Tennessee | 37076 | — |
| Pfizer Investigational Site | Hixson | Tennessee | 37343 | — |
| Pfizer Investigational Site | Lebanon | Tennessee | 37087 | — |
| Pfizer Investigational Site | Murfreesboro | Tennessee | 37130 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37203 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37205 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37207 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37211 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37232 | — |
| Pfizer Investigational Site | Paris | Tennessee | 38242 | — |
| Pfizer Investigational Site | Smyrna | Tennessee | 37167 | — |
| Pfizer Investigational Site | Union City | Tennessee | 38261 | — |
| Pfizer Investigational Site | Corpus Christi | Texas | 78463 | — |
| Pfizer Investigational Site | Mechanicsville | Virginia | 23116 | — |
| Pfizer Investigational Site | Midlothian | Virginia | 23114 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23230 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00615056, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2013 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00615056 live on ClinicalTrials.gov.